Abeona Therapeutics Shares Outstanding 2010-2022 | ABEO
Abeona Therapeutics shares outstanding from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Abeona Therapeutics Annual Shares Outstanding
(Millions of Shares) |
| 2021 |
98 |
| 2020 |
93 |
| 2019 |
50 |
| 2018 |
48 |
| 2017 |
42 |
| 2016 |
34 |
| 2015 |
28 |
| 2014 |
2 |
| 2013 |
1 |
| 2012 |
0 |
| 2011 |
0 |
| 2010 |
0 |
| 2009 |
0 |
Abeona Therapeutics Quarterly Shares Outstanding
(Millions of Shares) |
| 2022-03-31 |
145 |
| 2021-12-31 |
98 |
| 2021-09-30 |
98 |
| 2021-06-30 |
97 |
| 2021-03-31 |
94 |
| 2020-12-31 |
93 |
| 2020-09-30 |
93 |
| 2020-06-30 |
93 |
| 2020-03-31 |
92 |
| 2019-12-31 |
50 |
| 2019-09-30 |
50 |
| 2019-06-30 |
49 |
| 2019-03-31 |
48 |
| 2018-12-31 |
48 |
| 2018-09-30 |
48 |
| 2018-06-30 |
47 |
| 2018-03-31 |
47 |
| 2017-12-31 |
42 |
| 2017-09-30 |
40 |
| 2017-06-30 |
40 |
| 2017-03-31 |
40 |
| 2016-12-31 |
34 |
| 2016-09-30 |
33 |
| 2016-06-30 |
33 |
| 2016-03-31 |
33 |
| 2015-12-31 |
28 |
| 2015-09-30 |
32 |
| 2015-06-30 |
26 |
| 2015-03-31 |
20 |
| 2014-12-31 |
2 |
| 2014-09-30 |
1 |
| 2014-06-30 |
1 |
| 2014-03-31 |
1 |
| 2013-12-31 |
1 |
| 2013-09-30 |
1 |
| 2013-06-30 |
1 |
| 2013-03-31 |
1 |
| 2012-12-31 |
0 |
| 2012-09-30 |
0 |
| 2012-06-30 |
0 |
| 2012-03-31 |
0 |
| 2011-12-31 |
0 |
| 2011-09-30 |
0 |
| 2011-06-30 |
0 |
| 2011-03-31 |
0 |
| 2010-12-31 |
0 |
| 2010-09-30 |
0 |
| 2010-06-30 |
1 |
| 2010-03-31 |
0 |
| 2009-12-31 |
0 |
| 2009-09-30 |
0 |
| 2009-06-30 |
0 |
| 2009-03-31 |
0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.022B |
$0.003B |
|
Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.
|
